search
Back to results

Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer

Primary Purpose

Stomach Neoplasms

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Laparoscopic Proximal Gastrectomy With Double-flap Technique
Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction
Sponsored by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stomach Neoplasms focused on measuring laparoscopy, minimally invasive surgical procedures, stomach neoplasm, Gastrectomy, Reflux Esophagitis

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 20 years ≤ age ≤ 80 years The primary gastric lesions were located in the proximal third of the stomach histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy) clinical stage IA (T1N0M0) or IB (T1N1M0 / T2N0M0) according to the 8th edition of the American Joint Committee on Cancer(AJCC) staging system(Clinical stage was determined based on the finding of endoscopic ultrasonography and/or thoraco-abdominal contrast-enhanced computed tomography) scheduled for laparoscopic proximal gastrectomy with D1+/D2 lymphadenectomy or laparoscopic total gastrectomy with D1+/D2 lymphadenectomy , and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition).). The preoperative American Society of Anesthesiologists (ASA) physical status was I-III; The patient's cardiopulmonary function can tolerate laparoscopic surgery. The patients have signed the informed consent form. Exclusion Criteria: history of upper abdominal surgery (except laparoscopic cholecystectomy); the tumor invades the esophagus 3cm above gastro-esophageal junction (Z-line) with other malignant diseases or have suffered from other malignant diseases within 5 years require simultaneous surgery due to complicated with other diseases women are pregnant or in lactation period Suffering from serious mental illness history of continuous systemic corticosteroid or immunosuppressive drug treatment within 1 month

Sites / Locations

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Laparoscopic Proximal Gastrectomy With Double-flap Technique

Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction

Arm Description

Outcomes

Primary Outcome Measures

The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively
During follow-up endoscopy 1 year after surgery, reflux esophagitis are graded according to the Los Angeles (LA) classification.

Secondary Outcome Measures

Quality of Life after Surgery
Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) 30-item core QoL (QLQ-C30 ver.3.0). Higher scores mean a worse outcome.
Gastrointestinal Symptoms after Surgery
gastrointestinal symptoms are assessed by Gastrointestinal Quality of Life Index (GIQLI) questionnaires. Higher scores mean a better outcome.
Changes in hemoglobin levels at Follow-up
blood hemoglobin(g/L) levels
Changes in Vitamin B12 levels at Follow-up
blood Vitamin B12(μg/ml) levels
Changes in total protein levels at Follow-up
blood total protein(g/L) levels
Changes in serum albumin levels at Follow-up
blood serum albumin(g/L) levels
Changes in prealbumin levels at Follow-up
blood prealbumin(g/L) levels
Late Postoperative Morbidity
adhesive ileus, anastomosis stenosis, malnutrition, dumping syndrome. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard.
Early Postoperative Morbidity
operation wound with seroma, hematoma, infection, dehiscence, or evisceration, anastomotic leakage, anastomotic bleeding, abdominal bleeding, abdominal abscess, intestinal obstruction morbidity, gastrointestinal bleeding, gastroparesis, postoperative pancreatitis, pancreatic fistula, chylous leakage, lung morbidity, cerebrovascular morbidity, cardiovascular morbidity, deep vein thrombosis, cholecystitis, liver dysfunction, kidney dysfunction. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard.
Short-term Clinical Outcome After Surgery
time to pass gas(hours)
Short-term Clinical Outcome After Surgery
time to oral intake(hours)
Short-term Clinical Outcome After Surgery
time to indwell gastric tube(hours)
Short-term Clinical Outcome After Surgery
length of postoperative hospitalisation(days)
Surgical Characteristics
operative time(minutes)
Surgical Characteristics
time for reconstruction the digestive tract(minutes) during surgery
Surgical Characteristics
blood loss(ml) during surgery
3-year disease-free survival rate
3-year disease-free survival rate
3-year overall survival rate
3-year overall survival rate
3-year recurrence pattern
3-year recurrence pattern
5-year disease-free survival rate
5-year disease-free survival rate
5-year overall survival rate
5-year overall survival rate
5-year recurrence pattern
5-year recurrence pattern
body mass index postoperatively
body mass index(kg/m^2)
Quality of Life postoperatively
Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) gastric cancer module (QLQ-STO22) questionnaire. Higher scores mean a worse outcome.
Postoperative pain assessment
We measured the pain score using visual analog scale(VAS) at 24 hours after the surgery is completed. Higher scores mean a worse outcome.
Pathological Characteristics
lymph nodes dissection extent for each patient in the surgery
Pathological Characteristics
number of dissected lymph nodes for each patient in the surgery
Pathological Characteristics
R0 resection rate. R0 resection represents complete resection of the tumor, meaning there is no residual tumor.
Proportion of participants die after surgery
mortality rate
Proportion of participants need to rehospitalized after surgery
rehospitalization rate.

Full Information

First Posted
May 3, 2023
Last Updated
May 26, 2023
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators
First Hospital of China Medical University, Tianjin Medical University Cancer Institute and Hospital, Liaoning Tumor Hospital & Institute, Sichuan Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Qilu Hospital of Shandong University, First Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Guangxi Medical University, Zunyi Medical College, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Hospital, Shandong Provincial Hospital, The First Affiliated Hospital of Zhengzhou University, Qinghai Province Cancer Hospital, LanZhou University
search

1. Study Identification

Unique Protocol Identification Number
NCT05890339
Brief Title
Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
Official Title
Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer: a Multi-center Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 10, 2023 (Anticipated)
Primary Completion Date
December 10, 2029 (Anticipated)
Study Completion Date
May 10, 2033 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators
First Hospital of China Medical University, Tianjin Medical University Cancer Institute and Hospital, Liaoning Tumor Hospital & Institute, Sichuan Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Qilu Hospital of Shandong University, First Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Guangxi Medical University, Zunyi Medical College, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Hospital, Shandong Provincial Hospital, The First Affiliated Hospital of Zhengzhou University, Qinghai Province Cancer Hospital, LanZhou University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Proximal early gastric cancer can choose radical total gastrectomy or proximal gastrectomy. But if use simple esophagogastric anastomosis for proximal gastrectomy, the incidence of postoperative reflux esophagitis is up to 62%, which seriously affects the quality of life, and the short-term outcome is poorer than the total gastrectomy. If the incidence of postoperative reflux esophagitis can be reduced, proximal gastrectomy would be the treatment choice for proximal early gastric cancer, which may more improve both quality of life and nutritional status than total gastrectomy. Double-flap technique is a new surgical procedure for the reconstruction between esophagus and remnant stomach, which was started to be applied to digestive tract reconstruction in patients with proximal early gastric cancer in 2016. It can reduce the occurrence of reflux oesophagitis. At present, the studies for double-flap technique in China and other countries are mostly retrospective studies, and there are short of large-scale prospective studies and evidence of evidence-based medicine. The applicant has initiated a phase II, single center, single arm study and the results suggested that the laparoscopic proximal gastrectomy with double-flap reconstruction technique was safe and effective for treating proximal early gastric cancer. To further validate the short and long-term outcomes of this procedure, a multicentre, open label, prospective, superiority and randomised controlled clinical trial was set up to compare laparoscopic proximal gastrectomy with double-flap technique with laparoscopic total gastrectomy with Roux-en-Y reconstruction for proximal early gastric cancer. It include 216 patients with proximal early gastric cancer. The primary outcome is the proportion of patients who develop reflux esophagitis within 12 months after surgery. The short and long-term oncological outcomes are also explored. This trial can provide high-grade evidence of evidence-based medicine for double-flap technique's clinical applications .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stomach Neoplasms
Keywords
laparoscopy, minimally invasive surgical procedures, stomach neoplasm, Gastrectomy, Reflux Esophagitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
216 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Laparoscopic Proximal Gastrectomy With Double-flap Technique
Arm Type
Experimental
Arm Title
Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Proximal Gastrectomy With Double-flap Technique
Intervention Description
Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA:Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p;D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction
Intervention Description
Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA:Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p;D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
Primary Outcome Measure Information:
Title
The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively
Description
During follow-up endoscopy 1 year after surgery, reflux esophagitis are graded according to the Los Angeles (LA) classification.
Time Frame
12 months postoperatively
Secondary Outcome Measure Information:
Title
Quality of Life after Surgery
Description
Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) 30-item core QoL (QLQ-C30 ver.3.0). Higher scores mean a worse outcome.
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Title
Gastrointestinal Symptoms after Surgery
Description
gastrointestinal symptoms are assessed by Gastrointestinal Quality of Life Index (GIQLI) questionnaires. Higher scores mean a better outcome.
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Title
Changes in hemoglobin levels at Follow-up
Description
blood hemoglobin(g/L) levels
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Changes in Vitamin B12 levels at Follow-up
Description
blood Vitamin B12(μg/ml) levels
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Changes in total protein levels at Follow-up
Description
blood total protein(g/L) levels
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Changes in serum albumin levels at Follow-up
Description
blood serum albumin(g/L) levels
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Changes in prealbumin levels at Follow-up
Description
blood prealbumin(g/L) levels
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Late Postoperative Morbidity
Description
adhesive ileus, anastomosis stenosis, malnutrition, dumping syndrome. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard.
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Early Postoperative Morbidity
Description
operation wound with seroma, hematoma, infection, dehiscence, or evisceration, anastomotic leakage, anastomotic bleeding, abdominal bleeding, abdominal abscess, intestinal obstruction morbidity, gastrointestinal bleeding, gastroparesis, postoperative pancreatitis, pancreatic fistula, chylous leakage, lung morbidity, cerebrovascular morbidity, cardiovascular morbidity, deep vein thrombosis, cholecystitis, liver dysfunction, kidney dysfunction. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard.
Time Frame
From surgery to discharge, up to 30 days
Title
Short-term Clinical Outcome After Surgery
Description
time to pass gas(hours)
Time Frame
From surgery to discharge, up to 30 days
Title
Short-term Clinical Outcome After Surgery
Description
time to oral intake(hours)
Time Frame
From surgery to discharge, up to 30 days
Title
Short-term Clinical Outcome After Surgery
Description
time to indwell gastric tube(hours)
Time Frame
From surgery to discharge, up to 30 days
Title
Short-term Clinical Outcome After Surgery
Description
length of postoperative hospitalisation(days)
Time Frame
From surgery to discharge, up to 30 days
Title
Surgical Characteristics
Description
operative time(minutes)
Time Frame
24 hours postoperatively
Title
Surgical Characteristics
Description
time for reconstruction the digestive tract(minutes) during surgery
Time Frame
24 hours postoperatively
Title
Surgical Characteristics
Description
blood loss(ml) during surgery
Time Frame
24 hours postoperatively
Title
3-year disease-free survival rate
Description
3-year disease-free survival rate
Time Frame
3 years
Title
3-year overall survival rate
Description
3-year overall survival rate
Time Frame
3 years
Title
3-year recurrence pattern
Description
3-year recurrence pattern
Time Frame
3 years
Title
5-year disease-free survival rate
Description
5-year disease-free survival rate
Time Frame
5 years
Title
5-year overall survival rate
Description
5-year overall survival rate
Time Frame
5 years
Title
5-year recurrence pattern
Description
5-year recurrence pattern
Time Frame
5 years
Title
body mass index postoperatively
Description
body mass index(kg/m^2)
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Title
Quality of Life postoperatively
Description
Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) gastric cancer module (QLQ-STO22) questionnaire. Higher scores mean a worse outcome.
Time Frame
Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Title
Postoperative pain assessment
Description
We measured the pain score using visual analog scale(VAS) at 24 hours after the surgery is completed. Higher scores mean a worse outcome.
Time Frame
Day 1 postoperatively
Title
Pathological Characteristics
Description
lymph nodes dissection extent for each patient in the surgery
Time Frame
1 week postoperatively
Title
Pathological Characteristics
Description
number of dissected lymph nodes for each patient in the surgery
Time Frame
1 week postoperatively
Title
Pathological Characteristics
Description
R0 resection rate. R0 resection represents complete resection of the tumor, meaning there is no residual tumor.
Time Frame
1 week postoperatively
Title
Proportion of participants die after surgery
Description
mortality rate
Time Frame
From surgery to discharge, up to 30 days
Title
Proportion of participants need to rehospitalized after surgery
Description
rehospitalization rate.
Time Frame
From surgery to discharge, up to 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 20 years ≤ age ≤ 80 years The primary gastric lesions were located in the proximal third of the stomach histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy) clinical stage IA (T1N0M0) or IB (T1N1M0 / T2N0M0) according to the 8th edition of the American Joint Committee on Cancer(AJCC) staging system(Clinical stage was determined based on the finding of endoscopic ultrasonography and/or thoraco-abdominal contrast-enhanced computed tomography) scheduled for laparoscopic proximal gastrectomy with D1+/D2 lymphadenectomy or laparoscopic total gastrectomy with D1+/D2 lymphadenectomy , and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition).). The preoperative American Society of Anesthesiologists (ASA) physical status was I-III; The patient's cardiopulmonary function can tolerate laparoscopic surgery. The patients have signed the informed consent form. Exclusion Criteria: history of upper abdominal surgery (except laparoscopic cholecystectomy); the tumor invades the esophagus 3cm above gastro-esophageal junction (Z-line) with other malignant diseases or have suffered from other malignant diseases within 5 years require simultaneous surgery due to complicated with other diseases women are pregnant or in lactation period Suffering from serious mental illness history of continuous systemic corticosteroid or immunosuppressive drug treatment within 1 month
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Han Fanhai, Professor
Phone
+86-135-8031-7677
Email
fh_han@163.com
Facility Information:
Facility Name
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
City
Guangzhou
State/Province
Guangdong
Country
China

12. IPD Sharing Statement

Learn more about this trial

Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer

We'll reach out to this number within 24 hrs